Humacyte, Inc. (HUMA)
After hours:
| Previous close | 7.05 |
| Open | 6.70 |
| Bid | 6.12 x 400 |
| Ask | 6.25 x 300 |
| Day's range | 6.04 - 6.79 |
| 52-week range | 1.96 - 9.97 |
| Volume | |
| Avg. volume | 2,121,930 |
| Market cap | 737.13M |
| Beta (5Y monthly) | 1.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
GlobeNewswireCenters for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantabl
Simply Wall St.This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate
Key Insights Humacyte to hold its Annual General Meeting on 11th of June Salary of US$603.8k is part of CEO Laura...
GuruFocus.comInsider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)
On May 31, 2024, Heather Prichard, Chief Operating Officer of Humacyte Inc (NASDAQ:HUMA), sold 191,511 shares of the company, according to the SEC Filing.
